Corporate Compliance

Medical testing company will pay $302M to settle false marketing case

Compliance Monitor, April 22, 2009

Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!

Quest Diagnostics will pay $302 million to settle civil charges of misleading marketing and criminal charges of misbranding, according to a Department of Justice (DOJ) release.
 
Quest also entered into a corporate integrity agreement with the OIG as part of the settlement.
 
The settlement resolves allegations that Quest and its subsidiary company, Nichols Institute Diagnostics, knowingly marketed a diagnostic test kit, used to measure parathyroid hormone levels in patients, as being more accurate than is actually was, according to the DOJ.



Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!

Most Popular

Related Articles